Gian Paolo Caviglia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2648305/publications.pdf

Version: 2024-02-01

230014 312153 2,404 129 27 41 citations g-index h-index papers 132 132 132 3189 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. Gut, 2022, 71, 382-390.	6.1	113
2	Shared microbiological and immunological patterns in periodontitis and IBD: A scoping review. Oral Diseases, 2022, 28, 1029-1041.	1.5	21
3	Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification. Minerva Gastroenterology, 2022, 68, .	0.3	2
4	Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. Digestive and Liver Disease, 2022, 54, 1101-1108.	0.4	12
5	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 635.	1.0	12
6	Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Cancers, 2022, 14, 828.	1.7	15
7	Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. Current Oncology, 2022, 29, 1422-1429.	0.9	11
8	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. Biomedicines, 2022, 10, 792.	1.4	4
9	Surveillance of cirrhotic patients using the protein induced by vitamin K absence or antagonist II (PIVKA-II). Minerva Medica, 2022, 113, 106-108.	0.3	O
10	Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in) Tj ETQq0 0 0 rg	BT /Overlo	ock 10 Tf 50 3
11	Special Issue "Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice― Journal of Clinical Medicine, 2022, 11, 2797.	1.0	O
12	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clinical Gastroenterology and Hepatology, 2021, 19, 46-60.e8.	2.4	27
13	Targeting ILâ€10, ZOâ€1 gene expression and ILâ€6/STATâ€3 transâ€signalling by a combination of atorvastatin mesalazine to enhance antiâ€inflammatory effects and attenuate progression of oxazoloneâ€induced colitis. Fundamental and Clinical Pharmacology, 2021, 35, 141-142.	and 1.0	3
14	Seronegative occult hepatitis C virus infection: what is its clinical relevance?. Minerva Biotecnologica, 2021, 32, .	1.2	0
15	Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 1818.	1.8	6
16	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology, 2021, 10, 215.	1.3	4
17	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites, 2021, 11, 155.	1.3	44
18	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101611.	0.7	0

#	Article	IF	Citations
19	Inflammatory Bowel Disease Nurseâ€"Practical Messages. Nursing Reports, 2021, 11, 229-241.	0.8	8
20	Tight junction regulation in celiac disease: role of larazotide acetate. Minerva Gastroenterology, 2021, , .	0.3	1
21	Elastography for characterization of focal liver lesions: current evidence and future perspectives. Minerva Gastroenterology, 2021, 67, .	0.3	9
22	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers, 2021, 13, 2305.	1.7	24
23	Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progression. Minerva Gastroenterology, 2021, , .	0.3	0
24	A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. Life, 2021, 11, 650.	1.1	1
25	Is the pattern of liver disease etiology changing in China?. Minerva Medica, 2021, 112, 521.	0.3	0
26	Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. Journal of Clinical Medicine, 2021, 10, 3308.	1.0	6
27	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. Journal of Clinical Medicine, 2021, 10, 3387.	1.0	16
28	Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2021, 10, 3257.	1.0	2
29	Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis. RMD Open, 2021, 7, e001755.	1.8	12
30	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 75, 786-794.	1.8	100
31	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. Journal of Advanced Research, 2021, 33, 183-187.	4.4	16
32	Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. Diagnostics, 2021, 11, 187.	1.3	9
33	Incremental value of HBcrAg to classify 1582 HBeAgâ€negative individuals in chronic infection without liver disease or hepatitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 733-744.	1.9	18
34	Faecal miRNA profiles associated with age, sex, BMI, and lifestyle habits in healthy individuals. Scientific Reports, 2021, 11, 20645.	1.6	16
35	Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. Journal of Clinical Medicine, 2021, 10, 4961.	1.0	8
36	Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. Pharmaceuticals, 2021, 14, 1230.	1.7	4

#	Article	IF	Citations
37	Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics, 2021, 11, 2185.	1.3	2
38	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. Frontiers in Endocrinology, 2021, 12, 716533.	1.5	27
39	Cytokines and Biologic Therapy in Patients with Inflammatory Bowel Diseases. Gastroenterology Insights, 2021, 12, 443-445.	0.7	3
40	Elastography for characterization of focal liver lesions: current evidence and future perspectives. Minerva Gastroenterology, 2021, 67, 196-208.	0.3	3
41	Risk of drug interactions and prescription appropriateness in elderly patients. Irish Journal of Medical Science, 2020, 189, 953-959.	0.8	16
42	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers, 2020, 12, 2776.	1.7	14
43	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. International Journal of Molecular Sciences, 2020, 21, 8838.	1.8	22
44	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. Journal of Clinical Medicine, 2020, 9, 2353.	1.0	18
45	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2020, 115, 1289-1292.	0.2	9
46	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. Journal of Clinical Medicine, 2020, 9, 3941.	1.0	34
47	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers, 2020, 12, 3218.	1.7	27
48	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, $9,1323$.	1.0	20
49	Treatment of hepatitis D: an unmet medical need. Clinical Microbiology and Infection, 2020, 26, 824-827.	2.8	18
50	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 800.	1.0	29
51	Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. Medicina (Lithuania), 2020, 56, 285.	0.8	11
52	Hepatitis D virus in Uzbekistan. The Lancet Gastroenterology and Hepatology, 2020, 5, 238-240.	3.7	1
53	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114985.	0.8	14
54	Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. Journal of Molecular Medicine, 2020, 98, 595-612.	1.7	31

#	Article	IF	Citations
55	Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn�s disease: an observational study. Revista Espanola De Enfermedades Digestivas, 2020, 112, 195-200.	0.1	26
56	Molecular mechanisms of hepatic fibrosis in chronic liver diseases. Minerva Biotecnologica, 2020, 32, .	1.2	33
57	Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease. Clinical Laboratory, 2020, 66, .	0.2	5
58	Strategies for <i>Helicobacter pylori </i> eradication in the year 2020. Saudi Journal of Gastroenterology, 2020, 26, 63.	0.5	5
59	Edaravone and MAPK pathway: the key role of gut permeability. Minerva Medica, 2020, 111, 181.	0.3	1
60	Role of immunoglobulin indexes in patients with chronic hepatitis B. Minerva Medica, 2020, 111, 382-383.	0.3	0
61	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. Medicina (Lithuania), 2019, 55, 441.	0.8	12
62	Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. Journal of Clinical Medicine, 2019, 8, 1646.	1.0	50
63	The medical impact of hepatitis D virus infection in Uzbekistan. Liver International, 2019, 39, 2077-2081.	1.9	19
64	Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index. Scandinavian Journal of Gastroenterology, 2019, 54, 1339-1345.	0.6	6
65	THU-208-Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA. Journal of Hepatology, 2019, 70, e254-e255.	1.8	1
66	Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scandinavian Journal of Gastroenterology, 2019, 54, 407-413.	0.6	46
67	HLAâ€DQ Genotyping, Duodenal Histology, and Response to Exclusion Diet in Autistic Children With Gastrointestinal Symptoms. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 39-44.	0.9	11
68	Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. Journal of Hepatology, 2019, 70, 793-795.	1.8	4
69	Reply to: "Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition― Journal of Hepatology, 2019, 70, 559-560.	1.8	0
70	Serum zonulin in patients with inflammatory bowel disease: a pilot study. Minerva Medica, 2019, 110, 95-100.	0.3	66
71	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. Minerva Medica, 2019, 110, 401-409.	0.3	22
72	Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnologica, 2019, 31, .	1.2	24

#	Article	IF	CITATIONS
73	Detection of gastrointestinal cancer: the role of cancer biomarkers. Minerva Biotecnologica, 2019, 31,	1.2	5
74	Physiopathology of intestinal barrier and the role of zonulin. Minerva Biotecnologica, 2019, 31, .	1.2	66
75	Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test. Minerva Biotecnologica, 2019, 31, .	1.2	12
76	Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message. Minerva Biotecnologica, 2019, 31, .	1.2	7
77	Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience. Minerva Gastroenterologica E Dietologica, 2019, 65, 77-78.	2.2	3
78	Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scandinavian Journal of Gastroenterology, 2018, 53, 734-740.	0.6	34
79	Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. Journal of Hepatology, 2018, 69, 301-307.	1.8	126
80	Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. Cancer Biomarkers, 2018, 21, 603-612.	0.8	24
81	Usefulness of the index of <scp>NASH</scp> – <scp>ION</scp> for the diagnosis of steatohepatitis in patients with nonâ€alcoholic fatty liver: An external validation study. Liver International, 2018, 38, 715-723.	1.9	22
82	The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. Scandinavian Journal of Gastroenterology, 2018, 53, 141-146.	0.6	16
83	Considerations about alcohol abstinence and liver disease. Minerva Psychiatry, 2018, 59, .	0.3	0
84	Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma. Minerva Biotecnologica, 2018, 30, .	1.2	13
85	Fecal calprotectin: beyond intestinal organic diseases. Panminerva Medica, 2018, 60, 29-34.	0.2	41
86	Basic and clinical aspects of resistin. Minerva Biotecnologica, 2018, 30, .	1.2	5
87	Management of Helicobacter pylori in Piedmont, Italy. Minerva Gastroenterologica E Dietologica, 2018, 64, 235-250.	2.2	11
88	Comment on "Changes in acute viral hepatitis epidemiology in the Turkish adult population: A multicenter study― Turkish Journal of Gastroenterology, 2018, 29, 719-719.	0.4	1
89	Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA. Clinical Laboratory, 2018, 64, 411-412.	0.2	6
90	Hepatitis B coreâ€related antigen kinetics in chronic hepatitis B virus genotype Dâ€infected patients treated with nucleos(t)ide analogues or pegylatedâ€interferonâ€Î±. Hepatology Research, 2017, 47, 747-754.	1.8	20

#	Article	IF	CITATIONS
91	Biochemical markers of bone metabolism during early orthodontic tooth movement with aligners. Angle Orthodontist, 2017, 87, 74-81.	1.1	30
92	Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test. Minerva Medica, 2017, 108, 489-495.	0.3	17
93	Non-organ-specific autoimmunity in patients suffering from gastric ulcer with and without Helicobacter pylori infection. Minerva Biotechnology and Biomolecular Research, 2017, 29, .	0.3	7
94	Hepatitis B core-related antigen: a novel biomarker for chronic hepatitis B treatment. Minerva Gastroenterology, 2017, 63, 169-171.	0.3	1
95	Liver fibrosis: the 2017 state of art. Panminerva Medica, 2017, 59, 320-331.	0.2	53
96	Role of serum hepatitis B core-related antigen in chronic hepatitis B infection. Minerva Biotechnology and Biomolecular Research, 2017, 30, .	0.3	3
97	Role and function of exosomal miR-9-3p in hepatocellular carcinoma. Minerva Medica, 2017, 109, 4-6.	0.3	3
98	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Medica, 2017, 59, 283-289.	0.2	35
99	Helicobacter pylori, gastric cancer and gastric cancer stem cells. Minerva Biotechnology and Biomolecular Research, 2017, 29, .	0.3	3
100	Chronic Hepatitis B Treatment: Current Perspectives on Telbivudine. İstanbul Medical Journal, 2017, 18, 189-195.	0.1	0
101	Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase. Biochemia Medica, 2016, 26, 114-120.	1.2	11
102	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology, 2016, 63, 107-116.	3.6	67
103	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Digestive and Liver Disease, 2016, 48, 55-61.	0.4	19
104	Utilizzo del test per la quantificazione dell'M2-PK fecale nell'ambito di un programma di screening per il carcinoma colorettale in soggetti positivi al FIT. Rivista Italiana Della Medicina Di Laboratorio, 2016, 12, 119-121.	0.2	0
105	Highly sensitive alphaâ€fetoprotein, <i>Lens culinaris</i> agglutininâ€reactive fraction of alphaâ€fetoprotein and desâ€gammaâ€carboxyprothrombin for hepatocellular carcinoma detection. Hepatology Research, 2016, 46, E130-5.	1.8	52
106	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.4	32
107	Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014. World Journal of Gastroenterology, 2016, 22, 8187.	1.4	49
108	Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitisâ€)?. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 307.	0.5	3

#	Article	IF	CITATIONS
109	On "Diagnostic value of aberrant gene methylation in stool samples for colorectal cancer or adenomas". Panminerva Medica, 2016, 58, 102.	0.2	3
110	A Comment on the Letter. Archives of Iranian Medicine, 2016, 19, 886.	0.2	0
111	Re: El-Garem etÂal.: Seminal Helicobacter pylori Treatment Improves Sperm Motility in Infertile Asthenozoospermic Men (Urology 2014;84:1347-1350). Urology, 2015, 85, 1217.	0.5	4
112	Reply to: diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders. Scandinavian Journal of Gastroenterology, 2015, 50, 623-624.	0.6	1
113	Chronic hepatitis <scp>C</scp> virus infection and lymphoproliferative disorders: Mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and <scp>B</scp> â€cell nonâ€ <scp>H</scp> odgkin lymphoma. Journal of Gastroenterology and Hepatology (Australia). 2015. 30. 742-747.	1.4	19
114	Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scandinavian Journal of Gastroenterology, 2015, 50, 1376-1381.	0.6	35
115	Serum Cytokeratin-18 Levels for Liver Fibrosis Prediction. Hepatitis Monthly, 2015, 15, e30853.	0.1	2
116	Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. Annals of Hepatology, 2014, 13, 91-97.	0.6	12
117	Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scandinavian Journal of Gastroenterology, 2014, 49, 1419-1424.	0.6	54
118	Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. Digestive and Liver Disease, 2014, 46, 1020-1024.	0.4	14
119	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. Antiviral Research, 2014, 109, 7-14.	1.9	12
120	Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays. Journal of Clinical Virology, 2014, 60, 341-346.	1.6	22
121	Noninvasive assessment of liver fibrosis: key messages for clinicians. Polish Archives of Internal Medicine, 2014, 124, 329-335.	0.3	22
122	<i>IL28B</i> polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World Journal of Gastroenterology, 2014, 20, 13146.	1.4	20
123	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antiviral Research, 2013, 100, 114-119.	1.9	27
124	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 311-317.e1.	2.4	30
125	Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. Annals of Hepatology, 2013, 13, 91-7.	0.6	1
126	Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy. Hepatitis Monthly, 2012, 12, e7292.	0.1	9

#	Article	IF	CITATIONS
127	Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. Therapeutic Drug Monitoring, 2012, 34, 722-728.	1.0	31
128	Outcome of chronic delta hepatitis in Italy: A long-term cohort study. Journal of Hepatology, 2010, 53, 834-840.	1.8	122
129	DAT1 VNTR Polymorphisms in a European and an African Population: Identification of a New Allele. Human Biology, 2008, 80, 191-198.	0.4	12